The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% ...
Caleb Kasner and his brother Duncan Kasner move around a little differently than average kids. The two brothers have Duchenne ...
Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.
Irish Independent on MSN4d
I keep thinking about all the milestones he’s going to miss’ – Kilkenny family in a race against time to get life saving treatment for son (4)But their are two certainties that his family are struggling to come to terms with.William will likely be wheelchair-bound by the age of eight, only four years from now.It is also unlikely that ...
Skylin Lui (Class of 2026) is the junior class president at Carlmont and is a second-year journalist for Scot Scoop. She is currently employed at Doc's Bagels. In her free time, she enjoys reading ...
The ultimate goal for much ALS research is to find therapeutic interventions that can slow or reverse disease progression. In order to evaluate such interventions, disease progression biomarkers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback